中国医院用药评价与分析2024，Vol.24Issue(7)：827-832,6.DOI:10.14009/j.issn.1672-2124.2024.07.014
ABCB1基因多态性与紫杉醇类药物致乳腺癌患者骨髓抑制的相关性研究
Correlation of ABCB1 Gene Polymorphism and Myelosuppression with Taxanes Application in Breast Cancer Patients
摘要
Abstract
OBJECTIVE:To explore the correlation of ABCB1 gene polymorphism and myelosuppression with taxanes application in breast cancer patients.METHODS:From Oct.2019 to Dec.2022,a total of 160 patients diagnosed with breast cancer in Affiliated Taian Central Hospital of Qingdao University were retrospectively analyzed.All patients were treated with a taxanes drug-based regimen.Univariate and Logistic regression were used to analyze the correlation with myelosuppression such as ABCB1 genotype.The correlation was analyzed by using gene stratification.Linkage disequilibrium effect of ABCB1 genotype was analyzed by SHEsis online software.RESULTS:Body mass index,ABCB1 G2677T genotype and molecular subtype had an effect on myelosuppression with significant difference(P<0.05).Compared with patients receiving taxanes for injection(albumin-bound),the incidences of moderate-to-severe myelosuppression(P=0.03),moderate-to-severe leukopenia(P=0.01)and moderate-to-severe neutrophilia(P<0.05)were lower in liposomes of taxanes for injection;the incidence of myelosuppression in patients with ABCB12677TT genotype was higher than those with GT and GG genotypes(P<0.05),with statistically significant differences.There was linkage disequilibrium in ABCB1 loci,yet the difference between ABCB1 haplotypes and the occurrence of myelosuppressive in patients was not statistically significant(P>0.05).CONCLUSIONS:In patients with breast cancer,clinical assessment of adverse drug reactions of taxanes requires a comprehensive consideration of the patients'genotype and gene-gene interactions,in addition to body mass index,molecular subtype,and type of taxanes.关键词
乳腺癌/紫杉醇/多西他赛/不良反应/基因型Key words
Breast cancer/Taxanes/Docetaxel/Adverse drug reactions/Genotype分类
药学引用本文复制引用
张恕芳,耿晓宁,邰晓鹏,张林,刘伦,刘富垒..ABCB1基因多态性与紫杉醇类药物致乳腺癌患者骨髓抑制的相关性研究[J].中国医院用药评价与分析,2024,24(7):827-832,6.基金项目
山东省药品不良反应监测中心委托项目(No.药化-2022SDADRKY11) （No.药化-2022SDADRKY11）
山东省医学会治疗药物监测科研基金项目(No.YXH2020ZX060) （No.YXH2020ZX060）
泰安市科技创新发展计划项目(No.2021NS340) （No.2021NS340）
